Close Menu

NEW YORK – British life science reagents and tools company Abcam said today that it has signed an agreement to use BrickBio's proprietary bioconjugation platform to develop research and diagnostic products.

Abcam has also taken an undisclosed equity stake in BrickBio and will work with the company to further develop its platform.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.

LiveScience reports that a novel mutation in the LPL gene was uncovered in three siblings with very high triglyceride levels.

The president of Nankai University is embroiled in a data manipulation scandal, the South China Morning Post reports.

In PNAS this week: cytotoxic CD4 T cell signature in supercentenarians, evolutionary history of beetles, and more.